CTLA4 and hypophysitis: The observed incidence of hypophysitis varies from 1.8 to 5.6% for CTLA-4 blockade and from 7.7 to 10.5% for combination therapy, while in the case of PD-1 inhibitors, it ranges from 0.3 to 1.1% and <0.1% [45,46].